FKBP51 significantly influences glioma development and resistance to chemotherapy through the modulation of the NF-κB signaling route. Targeting FKBP51 could enhance the effectiveness of rapamycin treatment in glioma, providing a potential therapeutic strategy. The gene discussed is FKBP4; the disease is central nervous system cancer.